Physician profile
Kaitlin Springer
NPI 1831783778
$5,588.86
in general payments reported to CMS, 2019-2025
23 companies · $1,272 in 2025
The $1,272 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $222 · 2023: $2,960 · 2024: $1,135 · 2025: $1,272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,399 · Travel and Lodging: $750 · Education: $219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,398.52 |
| Travel and Lodging | $749.51 |
| Education | $219.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,563.63 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Pascal, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Cvrx, INC. | $700.28 | 2023-2025 | Barostim Neo System |
| Medtronic, INC. | $624.77 | 2022-2025 | Corevalve Evolut R, Mycarelink |
| Boston Scientific Corporation | $381.73 | 2023-2025 | Watchman Access System, Watchman Flx, Synergy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $359.53 | 2022-2025 | Lifevest |
| Amgen INC. | $306.36 | 2023-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $296.48 | 2022-2025 | Wainua, Farxiga |
| E.R. Squibb & Sons, L.L.C. | $276.09 | 2023-2025 | Camzyos, Eliquis |
| Pfizer INC. | $268.85 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.63 | 2023-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $126.82 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $102.65 | 2023-2025 | Verquvo, Belsomra, Capvaxive |
| Kiniksa Pharmaceuticals, LTD. | $74.98 | 2023 | Arcalyst |
| Impulse Dynamics (USA) INC. | $74.60 | 2023 | Optimizer |
| Abbott Laboratories | $68.97 | 2023-2025 | Cardiomems, Diamondback Coronary |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $51.70 | 2025 | |
| Cardiva Medical, INC. | $48.55 | 2024 | Savvywire |
| Scpharmaceuticals INC. | $23.65 | 2025 | |
| Shockwave Medical, INC | $20.90 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abiomed | $20.60 | 2023 | Impella |
| Bayer Healthcare Pharmaceuticals INC. | $20.10 | 2025 | |
| Sanofi-Aventis U.S. LLC | $19.22 | 2022 | |
| Novo Nordisk INC | $15.77 | 2023 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaitlin Springer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.